Clinical trial
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced…
NCT00044291 · Intarcia Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00044291 |
|---|---|
| Title | Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer |
| Lead sponsor | Intarcia Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Neoplasms, Hormone-dependent |
| Intervention type | Drug, Procedure |
| Interventions | atamestane, toremifene, letrozole, aromatase inhibition, hormone therapy, endocrine therapy, antiestrogen therapy |
| Enrollment | 865 |
| Start date | Jun 1, 2002 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Aug 27, 2002 |
| Last update posted | Jul 31, 2015 |
| Countries | Canada, Russia, Ukraine, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: